Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).
06-06-2021 | ASCO 2021 | Conference coverage | Video
06-06-2021 | ASCO 2021 | Conference coverage | Video
Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).